Alathary Ashraf, Al-Isawi Zahraa
DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, KUFA, IRAQ.
Wiad Lek. 2025;78(4):797-805. doi: 10.36740/WLek/202970.
Aim: To examine potential protective effect of Tirzepatide against obesity-induced metabolic dysfunction and hepatic inflammatory and apoptotic responses.
Materials and Methods: A total of 28 adult male Sprague-Dawley rats were employed and divided into four groups, normal control group involved seven rats fed a regular diet, while other rats received a high fat diet. Obese rats were separated into three groups after eight weeks of high fat diet: obesity, Tirzepatide (10 nmol/kg) s.c and vehicle groups, and treated for four weeks. Data regarding body weight, blood glucose, serum insulin, liver enzymes, and TNF-α, IL-1β and caspase-3 levels in the liver tissue were obtained.
Results: results revealed that Tirzepatide-treated obese rats exhibited significantly reduced body weight, blood glucose, serum insulin ALT, triglyceride, VLDL levels. Additionally, liver specimens from Tirzepatide group demonstrated lower levels of TNF-α, IL-1β and caspase-3 compared to obese untreated rats.
Conclusions: It concluded that Tirzepatide treatment mitigates the metabolic dysregulations induced by High Fat Diet, additionally; it ameliorates the inflammatory and apoptotic responses in hepatic tissue triggered by High Fat Diet.
旨在研究替尔泊肽对肥胖诱导的代谢功能障碍以及肝脏炎症和凋亡反应的潜在保护作用。
材料与方法:总共使用28只成年雄性斯普拉格-道利大鼠,分为四组,正常对照组有7只大鼠,给予常规饮食,其他大鼠给予高脂饮食。高脂饮食8周后,肥胖大鼠被分为三组:肥胖组、替尔泊肽(10 nmol/kg)皮下注射组和溶剂对照组,并进行为期4周的治疗。获取有关体重、血糖、血清胰岛素、肝酶以及肝组织中肿瘤坏死因子-α、白细胞介素-1β和半胱天冬酶-3水平的数据。
结果显示,替尔泊肽治疗的肥胖大鼠体重、血糖、血清胰岛素、谷丙转氨酶、甘油三酯、极低密度脂蛋白水平显著降低。此外,与未治疗的肥胖大鼠相比,替尔泊肽组的肝脏标本中肿瘤坏死因子-α、白细胞介素-1β和半胱天冬酶-3水平较低。
结论为替尔泊肽治疗减轻了高脂饮食诱导的代谢失调,此外,它改善了高脂饮食引发的肝脏组织中的炎症和凋亡反应。